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C-terminal calcium binding of α-synuclein
modulates synaptic vesicle interaction
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Alpha-synuclein is known to bind to small unilamellar vesicles (SUVs) via its N terminus,
which forms an amphipathic alpha-helix upon membrane interaction. Here we show that
calcium binds to the C terminus of alpha-synuclein, therewith increasing its lipid-binding
capacity. Using CEST-NMR, we reveal that alpha-synuclein interacts with isolated synaptic
vesicles with two regions, the N terminus, already known from studies on SUVs, and
additionally via its C terminus, which is regulated by the binding of calcium. Indeed, dSTORM
on synaptosomes shows that calcium mediates the localization of alpha-synuclein at the
pre-synaptic terminal, and an imbalance in calcium or alpha-synuclein can cause synaptic
vesicle clustering, as seen ex vivo and in vitro. This study provides a new view on the binding
of alpha-synuclein to synaptic vesicles, which might also affect our understanding of
synucleinopathies.
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A lpha-synuclein is a 140-residue protein, which constitutesthree major protein regions, the N terminus (aa 1–60), thenon-amyloid-β component (NAC) region (aa 61–95),
designated as the aggregation-prone region, and the C terminus
(aa 96–140). Alpha-synuclein is localized at the pre-synaptic
terminals1, and, while structurally disordered in solution2,3, it also
exists in a partially structured, membrane-bound form. Indeed,
alpha-synuclein can bind a variety of synthetic vesicles but
displays a preference to bind to small, highly curved synthetic
vesicles via its N terminus4–10. NMR studies of alpha-synuclein
binding to synaptic-like synthetic vesicles have shown that this
interaction is primarily triggered by the N-terminal residues,
but interactions propagate up to residue 98, with the central
region of the protein (residues 65–97) having a key role
in modulating the binding afﬁnity to the membrane11 and in
promoting the clustering of synaptic vesicles12.
Moreover, although it has been shown that the N terminus of
alpha-synuclein strongly interacts with lipid vesicles, it is
important to note that so far all research on alpha-synuclein–lipid
interactions has been carried out on synthetic lipid vesicles. It
thus has yet to be shown how alpha-synuclein interacts with
physiological synaptic vesicles which are clearly distinct from just
lipid vesicles13.
We hypothesized that calcium has a role in the normal
physiological function of alpha-synuclein as alpha-synuclein is
primarily localized at the pre-synaptic terminals where high
calcium ﬂuctuations occur, ranging up to hundreds of µM14,15,
and since calcium has been previously shown to bind to
alpha-synuclein at its C terminus16. In addition, it is not clear
what the calcium afﬁnity to alpha-synuclein is, whether the C
terminus is equally amenable to cations in the presence of
synaptic vesicles, and how exposure to calcium would interfere
with the synaptic vesicle binding capacity of alpha-synuclein.
To answer these questions, we investigated ﬁrstly the calcium-
binding properties of alpha-synuclein by NMR and mass
spectrometry (MS). We then explored whether and how
neutralization of negative charges on the C terminus impacts on
the interaction of alpha-synuclein with lipids and synaptic
vesicles. And ﬁnally, we tested whether the interaction of alpha-
synuclein with synaptic vesicles impacts on synaptic vesicle
homeostasis and on alpha-synuclein aggregation and toxicity
related to Parkinson’s disease (PD).
We show here that calcium interacts with the negatively
charged C terminus of alpha-synuclein, having a KD in the range
of 21 µM. Using synaptic vesicles isolated from rat brain, we
performed chemical exchange saturation transfer (CEST)
experiments in solution-state NMR, and show that the C
terminus of alpha-synuclein has an increased tendency to interact
with synaptic vesicles upon calcium binding. In the presence of
calcium, alpha-synuclein exhibited speciﬁc clustering at the pre-
synaptic terminal, which could be reversed by the addition of a
calcium chelator. In contrast, VAMP2, a synaptic vesicle marker,
was not affected by these calcium changes. These ﬁndings suggest
that the normal physiological role of alpha-synuclein is to act as a
calcium-dependent modulator of vesicle homeostasis at the
pre-synaptic terminal. Using ventral mesencephalic neurons, we
further show that treatment with dopamine, a neurotransmitter
relevant in PD pathology, promoted the clustering of alpha-
synuclein-positive vesicles. The latter was prevented by treatment
with isradipine, a voltage-gated calcium channel inhibitor.
Furthermore, lowering either the levels of alpha-synuclein or
calcium prevented dopamine toxicity, indicating that both
alpha-synuclein and calcium levels need to be ﬁnely balanced.
This study provides a new view on the binding of alpha-synuclein
to synaptic vesicles, which might also affect our understanding of
synucleinopathies.
Results
Calcium increases the lipid binding of alpha-synuclein. We
recorded 1H-15N heteronuclear single quantum correlation
(HSQC) spectra of alpha-synuclein in solution NMR as a func-
tion of calcium concentration to determine the thermodynamics
and structural nature of the calcium-binding mechanism. An
analysis of the spectra identiﬁed the C terminus as the primary
segment hosting chemical shift perturbations due to calcium
binding. In addition, we found peak broadening for some residues
in the NAC-region. Residues whose chemical shifts of the back-
bone amide N-H were mostly affected are aa 104, 107, 112, 119,
123, 124, 126, 127, 129, 130, 135, 136, 137 (Fig. 1a; Supplementary
Fig. 1). To obtain information on the thermodynamics of the
calcium afﬁnity to alpha-synuclein, and as the number of calcium
cations that are bound to alpha-synuclein was not known, we
performed a global analysis by ﬁtting the chemical shift
perturbation using a multiple ligand model17, which allows to
estimate the binding constant when the exact number of ligands
is not known. Similar models have also been used before to
analyze multivalent interactions of other amyloidogenic pro-
teins18. By performing best ﬁt analysis, we obtained a KD of
calcium afﬁnity of 21 µM with the number of ligand cations, L,
being 7.8 (Fig. 1b).
To provide further support on the number of ligand
cations being bound to alpha-synuclein we performed
electrospray ionization MS and found that at least six cations
are bound to alpha-synuclein (Fig. 1c; Supplementary Table 1).
We thus conﬁrmed by two independent measurements
that around 6–8 calcium ions can be bound to alpha-
synuclein providing further support of our determined KD. A
dissociation constant of 21 µM lies well within the range of
physiological pre-synaptic calcium ﬂuctuations, reaching up to
hundreds of µM in healthy neurons upon neuronal
stimulation14,15.
We then hypothesized that a neutralization of negative charges
on residues at the C terminus via dynamic binding of positively
charged calcium ions facilitates the interaction of alpha-synuclein
with phospholipid membranes. To test this hypothesis, we
incubated lipid Folch extracts from bovine brain with alpha-
synuclein in the presence of calcium and other ions, including
potassium, sodium, and magnesium and measured the interaction
of alpha-synuclein with lipids via lipid pull down. In the presence
of calcium, the amount of alpha-synuclein that precipitated with
the lipids increased about ﬁvefold. Magnesium and a high
concentration of sodium ions also increased the amount of
alpha-synuclein pulled down, but not to the same extent as
calcium (Fig. 1d; Supplementary Fig. 2). A phase partitioning
assay further established that the hydrophobicity of alpha-
synuclein increases upon calcium addition, which is manifested
by a higher abundance of the protein in the lipophilic detergent
phase (Supplementary Fig. 3).
The C terminus of alpha-synuclein binds to synaptic vesicles.
Having seen that calcium inﬂuences the binding of alpha-
synuclein to lipids, we investigated the interaction of alpha-
synuclein with synaptic vesicles isolated from rat brain and its
dependence on calcium. Using measurements of chemical
exchange saturation transfer (CEST) in solution NMR11,12, we
probed the binding afﬁnity along the protein sequence. This
analysis revealed that in the absence of calcium the interaction
with synaptic vesicles was strongest via the N terminus. In the
presence of calcium, however, the interaction of the C terminus
and also for some residues of the NAC-region was increased
(Fig. 2a), providing further insight into how calcium can modify
the C terminus of alpha-synuclein and thereby induce a stronger
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interaction with synaptic vesicles. To determine whether a
calcium-dependent lipid interaction is transient, and therefore
dynamically regulated, we again performed lipid pull-down
experiments. We show that, consistent with the fast exchange
regime observed in solution NMR, the calcium-dependent
interaction of alpha-synuclein is dynamic, as addition of the
calcium chelator EGTA reverses calcium-mediated alpha-synu-
clein lipid binding (Fig. 2b).
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Fig. 1 Calcium binding to the C terminus of alpha-synuclein and lipid binding. a 1H-15N HSQC NMR spectrum of alpha-synuclein in the absence (red) and in
the presence of calcium (green, 1.6 mM calcium). Major chemical shift perturbations in the presence of calcium are located at the C terminus of alpha-
synuclein (red arrows with assigned amino acid residues), whereas peak broadening (blue arrows with assigned amino acid residues) can be seen within
the NAC-region. b Fitting of alpha-synuclein calcium binding (KD) from 1H-15N HSQC NMR spectra at increasing calcium concentrations, where L indicates
the number of Ca2+ ions interacting with one alpha-synuclein molecule. c Calcium-bound alpha-synuclein species directly observed by mass spectrometry.
Electrospray ionization mass spectra were acquired under identical instrument conditions for samples incubated with or without calcium. Multiple alpha-
synuclein species were observed upon charge deconvolution of the ion envelope for the 9+–19+ charge states, inclusive. The masses correspond to alpha-
synuclein: calcium complexes up to a stoichiometry of 1:6. d Lipid pull-down experiment using lipids from Folch brain extracts, recombinant alpha-synuclein
and various ions. Western blot of the amount of protein pulled down shows that more alpha-synuclein was pulled down by the lipids in the presence of
calcium. Neither potassium, sodium, nor magnesium increased alpha-synuclein lipid binding to the same extent. **p= 0.0011, 0.0022, and 0.0090 for
comparison of 1 mM CaCl2 with alpha-syn control, 50mM KCl, and 150mM NaCl, respectively. Calculated using one-way ANOVA with Tukey’s post-hoc
correction, graphs indicate mean ± s.e.m. N= 3 for all groups, corresponding to three biological repeats, d.f. 12
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Alpha-synuclein is modulated by calcium at pre-synaptic
terminals. Synaptosomes, pinched off synapses that reseal as
spherical droplets, were isolated from rat brain and used to study
the synaptic localization of alpha-synuclein in the presence or
absence of calcium. Using direct stochastic optical reconstruction
microscopy (dSTORM), permitting sub-diffraction resolution
imaging, we found that under normal physiological conditions
(low intracellular and high extracellular calcium concentrations)
alpha-synuclein was signiﬁcantly polarized. This could be inter-
preted as if alpha-synuclein does not bind to synaptic vesicles,
however, our vitro data as well as data from previous reports5–10
show a strong binding of alpha-synuclein to synaptic vesicles. The
polarization could therefore be interpreted as a binding of alpha-
synuclein to only a subset of synaptic vesicles (similar to what has
been indicated in Lee et al.19). When we depleted calcium in the
extracellular buffer by the addition of the calcium chelator EGTA
and omitting calcium, alpha-synuclein displayed a dispersed
distribution throughout the synaptosome (Fig. 2c; Supplementary
Fig. 4).
The cluster sizes of the synaptosomal alpha-synuclein and
synaptic vesicle associated protein 2 (VAMP2), were determined
by cluster analysis and revealed that alpha-synuclein was
signiﬁcantly more dispersed upon calcium starvation with EGTA,
while calcium starvation had no effect on the localization of
VAMP2 (Fig. 2d). To address whether an increase in intracellular
calcium leads to a further clustering of alpha-synuclein,
we stimulated the synaptosomes with an extracellular solution
at 70 mM KCl, which leads to membrane depolarization and
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Fig. 2 The C terminus of alpha-synuclein binds to synaptic vesicles upon calcium binding. a CEST-NMR experiments were performed on alpha-synuclein
and synaptic vesicles in the absence (black) or presence of calcium (red, 6 mM). In the absence of calcium, the N terminus shows the strongest interaction
with synaptic vesicles. Upon addition of calcium, the interaction of the C terminus and also of some residues of the NAC-region increases, which is seen as
a reduction of the signal. Experiments were repeated twice. b Lipid pull-down experiment showing the transient nature of alpha-synuclein lipid binding.
Western blot of the amount of alpha-synuclein pulled down by the lipids showing that calcium-induced lipid binding of alpha-synuclein is reversible upon
addition of the calcium chelator EGTA. *p= 0.0263, calculated using one-way ANOVA with Tukey’s post-hoc correction, graphs indicate mean ± s.e.m. N
= 6 for control and CaCl2, n= 4 for EGTA and CaCl2+ EGTA, data from three biological repeats, d.f. 16. c dSTORM super-resolution imaging of alpha-
synuclein and VAMP2 on isolated synaptosomes displaying alpha-synuclein clustering under normal physiological conditions with 2.5 mM calcium in the
extracellular buffer (upper panel). Upon calcium depletion in the extracellular buffer, using 1 mM EGTA, alpha-synuclein localization was dispersed (lower
panel). d Cluster analysis of alpha-synuclein and VAMP2 immunostaining showing increased cluster size of alpha-synuclein upon calcium depletion,
whereas VAMP2 cluster size is the same either in the presence of calcium or upon calcium depletion in the extracellular buffer. ****p < 0.0001, nsp=
0.6363 calculated using two-tailed t-test, graphs indicate mean ± s.e.m. N= 22 for +Ca2+ and n= 30 for −Ca2+, where n indicates single synaptosomes,
data form three biological repeats, d.f. 50
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03111-4
4 NATURE COMMUNICATIONS |  (2018) 9:712 | DOI: 10.1038/s41467-018-03111-4 | www.nature.com/naturecommunications
calcium inﬂux via voltage-gated calcium channels. Our results
show that upon stimulation there is no further change in the
distribution of alpha-synuclein throughout the synaptosomes
(Supplementary Fig. 5), suggesting that normal physiological
calcium concentrations are sufﬁcient to induce alpha-synuclein
clustering. The speciﬁcity of the alpha-synuclein staining protocol
was validated using synaptosomes derived from alpha-synuclein
knockout mice (Supplementary Fig. 6). Furthermore, using
synaptosomes from wild-type human alpha-synuclein overex-
pressing mice, we see that alpha-synuclein loses its ability to be
speciﬁcally polarized under normal physiological conditions
(Supplementary Fig. 7).
Alpha-synuclein and calcium regulate synaptic vesicle inter-
action. Using NMR and synthetic lipids, we have shown recently
that alpha-synuclein is capable of tethering vesicles and two
protein regions were identiﬁed as participants in a double anchor
mechanism12. To quantify the dependencies of synaptic vesicle
clustering on calcium and alpha-synuclein, synaptic vesicles
puriﬁed from rat brains were incubated with either 1 mM EGTA
omitting calcium or 200 µM calcium and subsequently imaged
using stimulated emission depletion (STED) microscopy. For
samples incubated with EGTA 88% of synaptic vesicles were
distributed as single vesicles, whereas 12% showed clustering with
one or more vesicles. However, in the presence of calcium the
amount of single vesicles decreased to 84% and the number of
multiple vesicles clustering together increased to 16%. This
indicates that, even for synaptic vesicles isolated from wild-type
rat brain with endogenous levels of alpha-synuclein present,
calcium is a modulating factor of the cohesion between synaptic
vesicles. Next, we incubated synaptic vesicles with 200 µM of
calcium and 50 µM of recombinant alpha-synuclein, which, in
combination with the endogenous alpha-synuclein, leads to
doubling of the level of alpha-synuclein present on synaptic
vesicles13. Again, a signiﬁcant clustering of synaptic vesicles was
observed with 81% distributed as single synaptic vesicles and 19%
as multiple vesicle clusters. Incubating synaptic vesicles with 50
µM of recombinant alpha-synuclein and 1 mM EGTA in
combination, did however not reverse synaptic vesicle clustering,
indicating that the presence of an increased alpha-synuclein level
on its own can already induce synaptic vesicle clustering (Fig. 3a).
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A clustering of synaptic vesicles upon incubation with 50 µM of
alpha-synuclein was also observed via transmission electron
microscopy (Fig. 3b) and via combined confocal/STED imaging,
the latter verifying that synaptic vesicles colocalized with alpha-
synuclein (Fig. 3c).
Next, we studied the behavior of endogenous alpha-synuclein
in ventral midbrain (VM) neurons incubated with 100 µM
dopamine. This system has previously been shown to induce
the formation of alpha-synuclein oligomers and to exhibit
dopaminergic neuron-speciﬁc toxicity20–23. VM neurons treated
with dopamine for 72 h were stained against endogenous alpha-
synuclein and the synaptic vesicle protein synaptotagmin-1 and
subsequently imaged by dSTORM. Upon incubation with
dopamine, an increase in the area of alpha-synuclein-positive
puncta was observed, together with an increased size of
synaptotagmin-1 puncta and an increased co-localization of
alpha-synuclein and synaptotagmin-1 (Fig. 4a–c). We show that
these dopamine-induced changes were reversed by treating the
cells with isradipine, a CaV1.3 calcium channel antagonist
previously reported to block dopaminergic neuron cell death in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other
neurotoxin-related Parkinson’s disease models24. This demon-
strates that in the presence of endogenous alpha-synuclein levels
calcium is necessary to induce synaptic vesicle clustering,
consistent with our observations from isolated synaptic vesicles.
As isradipine was seen to signiﬁcantly reduce clustering of alpha-
synuclein, we tested if also dopamine-induced cytotoxicity might
be suppressed as a consequence of its action. Our data show that
dopamine-induced toxicity can be abolished both by the
administration of isradipine, or by knocking down of alpha-
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synuclein (Fig. 4d; Supplementary Fig. 8), indicating that high
levels of calcium and/or alpha-synuclein are key elements of
neuronal toxicity.
Calcium and synaptic vesicles affect alpha-synuclein aggrega-
tion. Taken together our data indicate that calcium mediates the
interaction of alpha-synuclein and synaptic vesicles and that this
has an effect in both physiological processes and under conditions
generating cellular toxicity. However, since both, either increased
levels of alpha-synuclein or calcium can induce cell death, we
investigated whether calcium and synaptic vesicles may inﬂuence
the aggregation propensity of alpha-synuclein. To test this
hypothesis, we performed Thioﬂavin T (ThT) ﬂuorescence assays
of alpha-synuclein aggregation, and analyzed the effect of
increased calcium in the presence and absence of synaptic vesicles
(Fig. 5a). The lag time for each condition was calculated from the
averaged aggregation curves by linear extension of the elongation
phase. The nucleation rate (k1) and the elongation rate (k2) were
ﬁtted using the Finke–Watzky equation for a two-step aggrega-
tion mechanism25. This analysis clearly revealed that calcium
aggravates alpha-synuclein aggregation, showing a lag time
decrease from 79 h for “EGTA only” to 4 h for “calcium only”.
Accordingly, the nucleation rate was increased 2-fold in
the presence of calcium, and the elongation rate was increased
1.3-fold. Moreover, the amount of residual monomer left at the
end of the aggregation assay was signiﬁcantly lower when calcium
was present, conﬁrming the higher aggregation propensity of
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Fig. 5 The effect of calcium and synaptic vesicles on alpha-synuclein aggregation. a Alpha-synuclein aggregation measured by ThT ﬂuorescence using 100
µMmonomeric alpha-synuclein under shaking conditions. The presence of 2.5 mM calcium increased the aggregation kinetics of alpha-synuclein compared
to 1 mM EGTA, both in the presence or absence of synaptic vesicles (black and red). For the EGTA-containing groups, there was a trend towards faster
aggregation of alpha-synuclein in the presence of synaptic vesicles (blue vs. gray). Three biological repeats, n= 18 for all conditions, where n represents
single wells. values represent mean ± s.e.m. b TEM images of alpha-synuclein ﬁbrils formed in the presence of 2.5 mM calcium or 1 mM EGTA either in the
presence or absence of synaptic vesicles. Differences in the morphology of alpha-synuclein ﬁbrils were observed for ﬁbrils formed in the presence of 2.5
mM calcium in the absence and presence of synaptic vesicles. In the presence of synaptic vesicles, alpha-synuclein ﬁbrils showed increased lateral
bundling and shortening. Alpha-synuclein aggregation in the presence of 1 mM EGTA led to substantially less ﬁbrils, however the ﬁbrils formed, retained
their morphological phenotype compared to the ﬁbrils formed in the presence of 2.5 mM calcium. Alpha-synuclein ﬁbrils formed in the presence of
synaptic vesicles plus 1 mM EGTA showed an intermediate phenotype, with bundled, but more elongated ﬁbril structures than found in the synaptic
vesicles and 2.5 mM calcium group. Experiments were repeated twice
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alpha-synuclein in the presence of calcium. In the presence
synaptic vesicles and calcium, we observed the highest nucleation
and elongation rate. In the absence of calcium, synaptic vesicles
decreased the lag time from 79 to 44 h and increased the
nucleation rate 2-fold compared to the “EGTA only” group,
which is in accordance with what has been reported for synthetic
vesicles17. However, the elongation rate was not increased
(Table 1).
Interestingly, alpha-synuclein ﬁbrils formed at the end of the
assay showed a different morphology when synaptic vesicles were
present during the aggregation process. When alpha-synuclein
was incubated in the presence of calcium and synaptic vesicles,
alpha-synuclein ﬁbrils were shorter and showed aggravated
bundling. In the presence of EGTA signiﬁcantly less ﬁbrils were
found. The few ﬁbrils that could be found in the EGTA group
without synaptic vesicles were long and separated whereas the
EGTA ﬁbrils formed in the presence of synaptic vesicles appeared
to have an intermediate phenotype as they were still bundled but
longer than the ﬁbrils formed in the presence of synaptic vesicles
and calcium (Fig. 5b). To conﬁrm the presence of synaptic
vesicles during the aggregation process we show a TEM image of
alpha-synuclein in the presence of synaptic vesicles at the
beginning of the aggregation experiment (Supplementary Fig. 9),
as after seven days the vesicles cannot be detected on the TEM
anymore.
Discussion
The C terminus of alpha-synuclein is negatively charged such that
electrostatic interaction can take place with cations16. In the past,
however, research on such interactions has predominantly been
focused on metal ions as environmental factors inducing alpha-
synuclein aggregation26–28. Here, we focus on the interaction of
alpha-synuclein with physiological calcium, since at the pre-
synaptic terminal, where alpha-synucleins primarily resides, large
ﬂuctuations in calcium levels are known to occur14,15. We
quantify and localize the interactions of calcium with alpha-
synuclein using 1H-15N HSQC NMR and observe signiﬁcant
chemical shift perturbations for a number of residues at the C
terminus of the protein. Furthermore, signiﬁcant peak broad-
ening takes place in the NAC-region of alpha-synucein in the
presence of calcium. This can be interpreted either as a con-
formational change in the NAC-region induced upon calcium
binding at the C terminus, or as an interaction between multiple
NAC-regions when individual alpha-synuclein molecules cluster
due to charge neutralization. The afﬁnity of calcium was found to
be around 21 µM, which is lower than reported for other multi-
valent cations27. Although levels of calcium are in the tens of nM
range under resting conditions29, it’s concentration rises to sev-
eral hundred µM within microdomains during depolarization of
neurons as a result of a concomitant calcium inﬂux via voltage-
gated calcium channels14,15. In this context, the observed KD of
21 µM highlights the physiological relevance of the interaction
between alpha-synuclein and calcium.
CEST-NMR experiments, analyzing the interaction of alpha-
synuclein with synaptic vesicles from rat brain, veriﬁed that in the
presence of calcium the C terminus has a higher afﬁnity to bind
to synaptic vesicles. In a previous study12 we have shown that the
modes of binding of the N-terminal and NAC-region of alpha-
synuclein to small unilammelar vesicles (SUVs) of DOPE:DOPS:
DOPC (in 5:3:2 molar ratios)11,12,30 are independent of each
other. This degree of independence suggested that the two regions
can bind the same vesicle but also multiple vesicles. We referred
to this N terminus and NAC-region binding of alpha-synuclein to
SUVs as double anchor mechanism. We now have characterized
the binding of alpha-synuclein to synaptic vesicles isolated from
rat brain using CEST-NMR, showing again that the strongest
binding occurs at the N terminus and revealing an intermediate
level of synaptic vesicle interaction of the NAC-region and the C
terminus. Interestingly, upon addition of calcium this binding via
the C terminus, and also for certain residues of the NAC-region,
was found to be increased. We refer to this as extended double
anchor mechanism since the double anchor has been extended to
the C terminus of alpha-synuclein. Our NMR data are consistent
with a study using site speciﬁc pyrene labeling of alpha-
synuclein31. In this study, it was shown that the N terminus of
alpha-synuclein binds to synthetic vesicles in the absence of
calcium, while the C terminus does not. Upon calcium addition
on its own, there is a reduction in the polarity of the C terminus,
which suggests calcium binding. Moreover, upon addition of
synthetic vesicles a further reduction in the polarity was observed,
supporting a calcium-dependent lipid binding of the C terminus.
Summarizing the above, alpha-synuclein, in the presence of cal-
cium, may act as an extended and strengthened double anchor
between synaptic vesicles, which could cause interaction in three
different ways: (i) the N terminus and C terminus both tether to
the same vesicle, (ii) the N terminus binds to one vesicle, whereas
the C terminus binds to another vesicle via an extended double
anchor mechanism, or (iii) the N terminus binds to synaptic
vesicles, whereas the C terminus binds to the plasma membrane.
Our observations, using synaptosomes, isolated synaptic vesicles
as well as ventral mesencephalic cells, suggest that calcium and
alpha-synuclein can affect vesicle pool homeostasis, either via
promoting intervesicular interactions and/or via tethering of
synaptic vesicles to the plasma membrane, which could inﬂuence
their proximity to voltage-gated calcium channels32.
From the time of its discovery, alpha-synuclein has been
known as a pre-synaptic protein, suggesting a role in neuro-
transmitter release. It has been shown that the overexpression of
alpha-synuclein inhibits neurotransmitter release33–37, whereas
neurotransmitter release appears facilitated in an alpha-synuclein
knockout model38–41. However, data are not conclusive so far and
a regulatory role rather than a direct role of alpha-synuclein in
exocytosis is still debated in the literature42. It has furthermore
Table 1 The effect of calcium and synaptic vesicles on alpha-synuclein aggregation
Condition Lag time (h) k1 (m/s) k2 (per s/%int) Remaining monomer (µM)
Ca2+ only 3.95±0.53 0.24±0.69 8.07±1.28 8.5±0.3****
Ca2++ SV 5.55±2.59 0.78±5.33 15.92±5.02 —a
EGTA only 78.95±0.42 0.09±0.04 6.32±0.65 67.8±5.4
EGTA+ SV 44.72±0.42 0.22±0.06 5.50±0.51 —a
ThT ﬂuorescence intensity proﬁles were used to calculate the lag time as well as the nucleation (k1) and the elongation rate (k2). Lag time is given as X intercept with standard error. k1 and k2 are given as
constants with a 95% conﬁdence interval. Three biological repeats. Remaining alpha-synuclein monomer concentration was revealed by analytical SEC-HPLC at the end of the experiment
****p < 0.0001, n = 10 for Ca2+ only, and n = 9 for EGTA only, where n indicates wells, two biological repeats, calculated using two-tailed t-test, values indicate mean ± s.e.m. d.f. 17
aRemaining monomer concentration could not be calculated due to presence of protein from synaptic vesicles preventing clear detection of remaining asyn monomer
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been suggested that alpha-synuclein has a role in endocytosis and
in synaptic vesicle homeostasis (for detailed review see ref. 43).
We show here, that in synaptosomes alpha-synuclein locali-
zation is dependent on calcium since calcium depletion in the
extracellular space does not lead to the polarization of alpha-
synuclein in the synaptosomes. It is interesting to note that we see
little overlap between alpha-synuclein and VAMP2, which could
be interpreted as if alpha-synuclein does not bind to synaptic
vesicles at all. We do, however, not believe that this is the case for
two main reasons: First, all our in vitro data as well as data from
others5–10 show strong binding of alpha-synuclein to synaptic
vesicles. Second, it has been suggested that alpha-synuclein binds
to only a subset of synaptic vesicles19, however, it may require
further investigations to fully determine which synaptic vesicles
are positive for which synaptic vesicle protein.
We show that calcium as well as increased alpha-synuclein
concentrations inﬂuence the clustering of synaptic vesicles
in vitro. Similar observations were made using synaptic vesicle-
mimics built of anionic phospholipids containing SNARE com-
plex proteins44. The authors showed that an increased alpha-
synuclein concentration caused clustering of the synaptic vesicle-
mimics, which was dependent on the capacity of alpha-synuclein
to bind to lipids, as the lipid-binding deﬁcient familial A30P
alpha-synuclein mutant displayed a decreased propensity to
cluster vesicles. The authors report that also C-terminally trun-
cated alpha-synuclein can decrease vesicle clustering, which
supports our hypothesis of an extended double anchor binding
mechanism of alpha-synuclein. The authors though indicate that
this is mediated via C-terminal binding of alpha-synuclein to
VAMP2. In our study, however, we do not observe clustering of
VAMP2, suggesting that a VAMP2-independent mechanism
might be involved. Our proposed model of alpha-synuclein-
dependent vesicle clustering is further supported by recent studies
demonstrating a decrease in synaptic vesicle motility in neurons
upon alpha-synuclein overexpression45,46. This is in line with our
observation that the overexpression of wild-type human alpha-
synuclein reduced the propensity of alpha-synuclein to be
polarized upon calcium treatment in synaptosomes. It is impor-
tant to note though that not all of these calcium-controlled
processes rely solely on the presence of alpha-synuclein. This
becomes clear from alpha-synuclein knockout studies in mice41,47
but is further supported by the fact, that alpha-synuclein is
expressed at late stages of development, as shown for songbirds,
for which alpha-synuclein becomes upregulated during song
acquisition48.
Furthermore, we show here that dopamine toxicity known to
induce alpha-synuclein oligomerization20–23 can be signiﬁcantly
reduced if either calcium levels are decreased, using the CaV1.3
blocker isradipine, or if alpha-synuclein levels are reduced by
knocking down alpha-synuclein, suggesting that both calcium
and alpha-synuclein need to be present to convey dopamine-
induced toxicity. This is in line with the ﬁndings that dopami-
nergic neurons of the substantia nigra (SN) display a lower
abundance of calcium-binding proteins49 and exhibit a calcium-
driven pacemaking activity50, putting them at higher risk for
calcium-mediated pathophysiology. Using in vitro aggregation
assays, we see that calcium clearly aggravates alpha-synuclein
aggregation, in the presence or absence of synaptic vesicles. We
also observed an increase in nucleation when synaptic vesicles
were added to alpha-synuclein with EGTA, which is in line with
the literature reporting that synthetic lipids increase the rate of
aggregation of alpha-synuclein17. Excess calcium can cause a
conformational change within the protein, such as by an exposure
of the NAC-region upon calcium binding, or simply via a change
in the net charge of the protein, both facilitating the propensity
for aggregation. It is interesting to note though that alpha-
synuclein ﬁbrils formed in vitro in the presence of isolated
synaptic vesicles display a different morphology.
Understanding the above described role of alpha-synuclein in
physiological or pathological processes may impact strongly on
the development of new therapeutics for PD. Interestingly, anti-
bodies targeted to the C terminus of alpha-synuclein were
demonstrated to decrease intracellular alpha-synuclein pathology
in animal models of synucleinopathy51. One such antibody,
PRX002, is currently in phase 2 clinical development for Par-
kinson’s disease (ClinicalTrials.gov Identiﬁer: NCT03100149).
Also isradipine, which is used as calcium channel blocker in heart
diseases, may prove to be a valuable candidate to act against PD
via lowering intracellular calcium load52,53 (ClinicalTrials.gov
Identiﬁer: NCT02168842).
Methods
Puriﬁcation of alpha-synuclein. Human wild-type (WT) alpha-synuclein was
expressed in Escherichia coli One Shot® BL21 STAR™ (DE3) (Invitrogen, Thermo
Fisher Scientiﬁc, Cheshire, UK) cells using plasmid pT7-7 and puriﬁed using ion
exchange on a HiPrep Q FF 16/10 anion exchange column (GE Healthcare,
Uppsala, Sweden)54. Alpha-synuclein was then further puriﬁed on a HiPrep Phenyl
FF 16/10 (High Sub) hydrophobic interaction column (GE Healthcare)55. Pur-
iﬁcation was performed on an ÄKTA Pure (GE Healthcare, Sweden). Monomeric
protein was dialyzed against 20 mM Na2HPO4 pH 7.2 and stored at −80 °C. For
experiments with dye-labeled alpha-synuclein, the cysteine mutant N122C was
puriﬁed and labeled with the ATTO-647N dye (#05316, Sigma-Aldrich, Dorset,
UK). For experiments with vesicles, monomeric human WT alpha-synuclein was
buffer exchanged using PD10 Desalting Columns (GE Healthcare) into vesicle
buffer (20 mM NaCl, 2.5 mM KCl, 25 mM HEPES, 30 mM Glucose, pH 7.4 with
NaOH).
Lipid pull-down assay. Lipid extract from bovine brain (Type I, Folch Fraction I;
Sigma-Aldrich) was dissolved in lipid buffer (1 mg/mL; 50 mM Tris+ 100 mM
NaCl, pH 7.4) and sonicated on ice using a Branson SLPe sonicator (Branson
Ultrasonic S.A., Geneva, Switzerland). The lipid was incubated with 2 µg of
recombinant human alpha-synuclein with either KCl (50 mM), NaCl (150 or 300
mM), MgCl2 (1 mM) or CaCl2 (1 mM), for 1 h at room temperature (RT). The
different samples were centrifuged for 20 min at 4000 ×g at RT to obtain the pellet
for analysis by Western blot. The lipid pull-down assay to prove reversibility of Ca2
+-dependent lipid binding was done using post-incubation with EGTA (5 mM) for
one 1 h.
Western blot of alpha-synuclein was performed using 4–12% Bis-Tris gels (Life
Technologies), the protein was transferred onto 0.2 µm Millipore PVDF membrane
(Fisher Scientiﬁc, Loughborough, UK) and subsequently ﬁxed using 4%
formaldehyde (Sigma-Aldrich) and 0.1% glutaraldehyde (Sigma-Aldrich). The
primary mouse anti-alpha-synuclein antibody LB509 (LB509, 1:1000 dilution, Life
Technologies) and an enhanced chemoluminescence (ECL)-horse radish
peroxidase (HRP) conjugated secondary antibody (NA931, 1:1000 dilution, GE
Healthcare) and SuperSignal West Femto Chemiluminescent Substrate (Thermo
Fisher Scientiﬁc, Epsom, UK) were used to probe the membrane, which was
exposed using a G:BOX (Syngene, Cambridge, UK).
Animals. Animals were bred and supplied by Charles River UK Ltd., Scientiﬁc,
Breeding and Supplying Establishment, registered under Animals (Scientiﬁc Pro-
cedures) Act 1986, and AAALAC International accredited. All animal work con-
formed to guidelines of animal husbandry as provided by the UK Home Ofﬁce.
Animals were sacriﬁced under schedule 1; procedures that do not require speciﬁc
Home Ofﬁce approval. Animal work was approved by the NACWO and University
of Cambridge Ethics Board.
Synaptic vesicles, synaptosomes, and cell cultures. Isolation of synaptic vesicles
(SV) was performed as previously described56. Brains were dissected from WT
Sprague-Dawley rats, two brains were used per SV preparation. The vesicle pellet was
resuspended in 200 µL of vesicle buffer (20mM NaCl, 2.5mM KCl, 25mM HEPES,
30mM Glucose, pH 7.4 with NaOH) and snap-frozen in aliquots in liquid nitrogen
before being stored at −80 °C. SVs had a protein concentration of 3.3mg/mL.
Synaptosomes were prepared from WT Sprague-Dawley adult rat brains as
described previously57. Brieﬂy, the brain was homogenized in a glass-Teﬂon
EUROSTAR20 homogenizer (IKA, Oxon, UK) in homogenizing buffer made from
sucrose/EDTA buffer (320 mM sucrose, 1 mM EDTA, 5 mM Tris, pH 7.4) with 50
mM DTT, using 10 strokes at 800 rpm. Synaptosomes were isolated using 3–23%
Percoll gradients. The synaptosome containing fractions were pooled and
resuspended in extracellular buffer solution (20 mM sodium HEPES, 130 mM
NaCl, 5 mM NaHCO3, 1.2 mM Na2HPO4, 1 mM MgCl2, 10 mM glucose, 5 mM
KCl, 2.5 mM CaCl2, pH 7.4). Synaptosomes were loaded onto eight well glass
bottom µ-slides (ibidi GmbH, Munich, Germany), which were cleaned with 1M
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KOH and coated with poly-L-lysine 0.01% solution (mol wt 70,000–150,000,
Sigma-Aldrich) over night at 4 °C. Synaptosomes were stimulated for 30 min at 37 °
C with extracellular solution made at either 5 mM KCl+ 2.5 mM CaCl2, 5 mM
KCl+ 1 mM EGTA or 70 mM KCl+ 2.5 mM CaCl2. Synaptosomes were then
ﬁxed with 4% formaldehyde (Sigma-Aldrich) in PBS. Fixation was quenched by
washing with 0.1 M glycine in PBS for 5 min.
Ventral mesencephalic (VM) neurons were dissected from E14 Sprague-Dawley
rat embryos. In brief, VM tissue was incubated in 0.1% trypsin (Worthington
Biochemical Corporation, Lakewood, USA) and 0.05% DNase (Sigma-Aldrich) in
DMEM (Sigma-Aldrich) for 20 min at 37 °C. Cells were washed four times with
0.05% DNase in DMEM and triturated until a single cell suspension was reached.
Neurons were seeded at 100,000 cells/well in LabTek II chambered coverglass
(Thermo Fisher Scientiﬁc) coated with poly-L-lysine 0.01% solution (mol wt
70,000–150,000, Sigma-Aldrich). Neurons were kept in DMEM with 10% fetal
bovine serum (FBS, 10270-106, Gibco®) for 3 h, then media was changed to
Neurobasal media Gibco® supplemented with 2% B27 Gibco®, 0.5 mM GlutaMax
Gibco® and 1% antibiotic-antimycotic Gibco® (all Thermo Fisher Scientiﬁc).
Neurons were used at days in vitro (DIV) 14. Fixation was performed for 10 min
using 4% formaldehyde (Sigma-Aldrich) in PBS containing 4% sucrose, 5 mM
MgCl2, and 10 mM EGTA.
Human neuroblastoma cells (SH-SY5Y) were obtained from the European
Collection of Cell Cultures (ECACC, Sigma-Aldrich) and grown in a 1:1 minimal
essential medium (MEM) (Sigma-Aldrich) and nutrient mixture F-12 Ham
(Sigma-Aldrich) supplemented with 15% FBS Gibco®, 1% non-essential amino-
acids Gibco®, 2 mM GlutaMAX Gibco®, and 1% antibiotic-antimycotic Gibco® (all
Thermo Fisher Scientiﬁc). Cells were plated at 5000 cells/well in Nunc MicroWell
96-well plates (Thermo Fisher Scientiﬁc) for cytotoxicity assays and at 700,000
cells/dish in 48 mm dishes (Nunc A/A) for western blotting studies. Cells were
tested for mycoplasma contamination.
Treatment of cells was performed using 100 µM dopamine (100× stock solution
in water, freshly prepared, Sigma-Aldrich) or 100 µM dopamine+ 5 µM isradipine
(1000× stock solution in DMSO, Sigma-Aldrich). Control cells received 0.1%
DMSO and 1% water, respectively. Isradipine treatment was carried out 30 min
early to dopamine treatment. After 72 h of incubation, cells were ﬁxed or
underwent cytotoxicity assay using the cell cytotoxicity assay kit, ab112118
(Abcam, Cambridge, UK) according to manufacturer’s instructions. Absorbance
intensity was measured at 570 nm and 605 nm, with the ratio OD570/OD605 being
proportional to the number of viable cells.
Solution NMR. To probe the structure and thermodynamics of calcium binding
with alpha-synuclein at a residue speciﬁc level, we employed a series of 1H-15N
HSQC experiments using different concentrations of Ca2+ (0–3.6 mM) and a ﬁxed
concentration of alpha-synuclein (200 μM). NMR experiments were carried out at
10 °C on a Bruker spectrometer operating at 1H frequencies of 800MHz equipped
with triple resonance HCN cryo-probe. The 1H-15N HSQC experiments were
recorded using a data matrix consisting of 2048 (t2, 1H) × 220 (t1, 15N) complex
points. Assignments of the resonances in 1H-15N-HSQC spectra of alpha-synuclein
were derived from our previous studies11.
The chemical shift perturbation in the 1H-15N HSQC spectra was analyzed
using a weighting function:
Δδ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
2
δ2H þ 0:15δ2N
 
r
:
These provide the fraction of bound alpha-synuclein, χB, which is calculated as:
χB ¼
Δδobs
Δδsat
:
Where the Δδobs is the variation of the chemical shifts of a peak of alpha-synuclein
that is observed at a given [Ca2+], and Δδsat is the maximum variation obtained at
saturation with an excess of calcium. χB was calculated as a function of [Ca
2+] for
every peak of the protein, and a global χB was used to include the chemical shift
variations from all the peaks associated with the major perturbations in the
presence of calcium. We then used a ﬁtting procedure based on a binding model
describing χB as a function of the total [Ca
2+]17
αsynU þ Ca2þL #αsynB Ca2þ
 
L: ð1Þ
Where αsynU and αsynB indicate free and calcium-bound alpha-synuclein, L
indicates the number of Ca2+ interacting with one alpha-synuclein molecule. The
equilibrium dissociation constant from this model is given by
KD ¼
αsynU½  Ca2þL
 
αsynB Ca2þð ÞL
  ; ð2Þ
the overall concentration of alpha-synuclein in this equilibrium is given by
αsyn½  ¼ αsynU þ αsynB Ca2þ L
 
; ð3Þ
and the overall concentration of Ca2+ is given by
Ca2þ
  ¼ L Ca2þ Lþ αsynB Ca2þ
 
L
  
: ð4Þ
Leading to the following ﬁtting function
χB ¼
αsyn½  þ Ca2þL
h i
þ KD 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
αsyn½  þ Ca2þL
h i
þ KD
 2
 4 αsyn½  Ca2þ½ L
r
2 αsyn½  :
Chemical exchange saturation transfer (CEST) NMR. CEST-NMR is widely
used to probe the interaction of amyoloidogenic proteins58,59. Here we employed
CEST measurements11,60–63 to directly probe the equilibrium between vesicle
unbound and bound states of alpha-synuclein. CEST has enhanced characteristics
compared to standard heteronuclear correlation spectroscopy in probing the details
of the equilibrium between NMR visible (unbound alpha-synuclein) and NMR
invisible (vesicle bound alpha-synuclein). These include a signiﬁcant sensitivity at
low vesicle:protein ratios and the avoidance of other factors that may inﬂuence the
transverse relaxation rates of the protein resonances. CEST experiments were
carried out at 10 °C on a Bruker spectrometer operating at 1H frequencies of 800
MHz equipped with triple resonance HCN cryo-probe. The measurements were
based on 1H-15N HSQC experiments by applying constant wave saturation of 400
Hz in the 15N channel. A series of large offsets was employed (−9, −7, −5, −4, −3,
−1.5, 0, 1.5, 3, 4, 5, 7, 9 kHz), and additional spectrum, saturated at −100 kHz, was
recorded as a reference. The saturation of the bound state is transferred to the free
state via the conformational exchange of these two states, resulting in the saturation
of the peak intensities in the visible unbound state. The CEST experiments were
recorded using a data matrix consisting of 2048 (t2, 1H) × 220 (t1, 15N) complex
points.
MS for the determination of alpha-synuclein–Ca complexes. Samples of 10 μΜ
wild-type alpha-synuclein in Tris buffer (20 mM, pH 7.4) were diluted in 50%
methanol/50% dH2O (v/v) to a ﬁnal concentration of 2 μM. Samples containing
3.6 mM CaCl2 were also prepared as described below. Stock solution of CaCl2 was
added to the alpha-synuclein sample and gently mixed with a micropipette, and
then incubated for 15 min at room temperature. The sample was then diluted with
50% methanol/50% dH2O (v/v) to a ﬁnal protein concentration of 2 μM before MS
analysis. The effect of formic acid concentration on the MS signal was also
investigated: for that reason, the previous samples were also prepared with formic
acid to ﬁnal concentrations of 0.01, 0.1 & 1% (v/v). Samples were infused into a
Synapt G2-Si mass spectrometer (Waters, USA) using a syringe pump (CorSolu-
tions, USA) at a ﬂow rate of 3.5 μL/min. Source temperature 80 °C, cone voltage 30
V, desolvation temperature 250 °C, trap collision energy 4 V, transfer collision
energy 4 V, Source pressure 7.7 × 10−6 bar, Trap pressure 8.8 × 10−6 bar, IMS cell
pressure 2.6 × 10−7 bar, Transfer pressure 8.7 × 10−6 bar. All data were collected in
positive ion mode.
Immunoﬂuorescence. Blocking and permeabilization were performed using 5%
serum and 0.01% digitonin in phosphate-buffered saline (PBS) for 1 h. Primary
antibodies were incubated for 1 h, followed by four washes with PBS. Secondary
antibodies were incubated for 10 min, followed by four washes with PBS. For
staining of synaptosomes no digitonin was used, instead all solutions contained
0.05% Tween-20. Samples were kept in PBS containing 5 mM sodium azide
(Sigma-Aldrich).
For STED imaging of synaptic vesicles, two primary antibodies, targeting the
two most abundant SV proteins13 synaptophysin (101002, 1:750 dilution, SYnaptic
SYstems, Goettingen, Germany) and VAMP2 (104202, 1:750 dilution, SYnaptic
SYstems) were used in purpose of improved signal to noise ratio. A secondary anti-
rabbit antibody conjugated with ATTO-647N (40839, 1:100 dilution, Sigma-
Aldrich) was used to detect both primary antibodies simultaneously. For combined
confocal/STED imaging of synaptic vesicles and alpha-synuclein, vesicles were
stained with a primary antibody for synaptotagmin-1 (105103, 1:500 dilution,
SYnaptic SYstems) and a secondary anti-rabbit antibody conjugated with Alexa-
488 (18772, 1:100 dilution, Sigma-Aldrich).
Synaptosomes were stained for alpha-synuclein (D37A6 XP®, 1:500 dilution,
rabbit, Cell Signalling, Danvers, US) and VAMP2 (104211, 1:500 dilution, mouse,
SYnaptic SYstems, Goettingen, Germany). As secondary antibodies anti-rabbit
Alexa Fluor®647 (ab150067, 1:200 dilution, Abcam) and anti-mouse Alexa
Fluor®568 (ab175700, 1:200 dilution, Abcam) were used.
VM neurons were stained for alpha-synuclein (ab6162, 1:300 dilution, sheep,
Abcam) and synaptotagmin-1 (105103, 1:500 dilution, rabbit, SYnaptic SYstems).
As secondary antibodies anti-sheep Alexa Fluor®647 (A21448, 1:200 dilution, Life
Technologies) and anti-rabbit Alexa Fluor®568 (A11036, 1:1000 dilution, Life
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Technologies) were used. Postﬁxation was performed with 4% formaldehyde
(Sigma-Aldrich) for 10 min to minimize the occurrence of detached ﬂuorophore
which would interfere with dSTORM imaging.
TEM, STED, and dSTORM. For transmission electron microscopy (TEM) imaging
of synaptic vesicles 1 µL of SVs (3.3 mg/mL) were incubated in 50 µL of vesicle
buffer at 37 °C with and without 50 µM monomeric alpha-synuclein for 4 days
without shaking. Overall, 10 µL of each sample was incubated on glow-discharged
carbon coated copper grids for 1 min before washing twice with dH2O. 2% uranyl
acetate was used to negatively stain the samples for 30 s before imaging on the
Tecnai G2 80-200kv TEM at the Cambridge Advanced Imaging Centre.
For stimulated emission depletion (STED) imaging 0.5 µL of SVs (3.3 mg/mL)
in 100 µL vesicle buffer were incubated with either 200 µM CaCl2 or 1 mM EGTA,
with or without 50 µM WT unlabeled alpha-synuclein. The mixture was taken up
and down a 30 G needle to disperse the SV, before incubating at 37 °C for 24 h
using Lo-Bind Protein Eppendorf tubes. Eight well glass bottom µ-slides (ibidi
GmbH, Munich, Germany) were coated with Biotin-PEG-cholesterol according to
the protocol described previously64 and synaptic vesicles were allowed to adhere for
1 h at RT. SVs were ﬁxed with 4% formaldehyde (Sigma-Aldrich) in PBS for 30 min
and washed three times with PBS, staining was performed as described above. For
combined confocal/STED imaging, 50 µM human WT alpha-synuclein was
complemented with 10% of alpha-synuclein N122C mutant labeled with ATTO-
647N dye (05316, Sigma-Aldrich). This allowed direct imaging of alpha-synuclein,
whereas synaptic vesicles were immunolabelled as described above. STED imaging
was performed on a home-built pulsed STED microscope12. STED excitation (λexc
= 640 nm) and depletion (λdepl= 765 nm) were generated from the same titanium
sapphire oscillator operating at 765 nm. The beam was divided between two paths.
In the excitation path, a supercontinuum was generated by pumping a photonic
crystal ﬁber (SCG800, NKT photonics, Cologne, Germany) and the excitation
wavelength was selected by a bandpass ﬁlter (637/7 BrightLine HC, Semrock, NY,
USA). Excitation and depletion pulse lengths were stretched to 56 and 100 ps
respectively through propagation in SF66 glass and polarization maintaining single
mode ﬁbers. The depletion beam was spatially shaped into a vortex beam by a
spatial light modulator (X10468 02, Hamamatsu Photonics, Hamamatsu City,
Japan) and the beams were recombined using a spatial light modulator. Imaging
was performed using a commercial point scanning microscope (Abberior
Instruments, Göttingen, Germany) comprising the microscope frame (IX83,
Olympus, Shinjiuku, Japan), a set of galvanometer mirrors (Quad scanner,
Abberior Instruments) and a detection unit. A ×100/1.4 NA oil immersion
objective (UPLSAPO 100XO, Olympus) and the Inspector software was used for
data acquisition (Andreas Schönle, Max Planck Institute for Biophysical Chemistry,
Göttingen, Germany). Fluorescence emission was descanned, focused onto a
pinhole and detected using an avalanche photodiode (SPCM-AQRH, Excelitas
Technologies. Waltham, USA). A ﬁeld of view of 20 × 20 µm2 and 20 nm pixel size
was used. Confocal images of ATTO488 labeled vesicles were correlated with STED
images. Images were acquired on the same system as described above. Fluorescence
excitation at 488 nm (Cobolt 06-MLD, Cobolt, Solna, Sweden). Fluorescence
emission was ﬁltered by a dichroic mirror (ZT594rdc, Chroma, Olching, Germany)
and a bandpass ﬁlter (FF01-550/88-25, Semrock). 6 images were analyzed per
condition for three experiments.
Direct stochastic optical reconstruction microscopy (dSTORM) was performed
as previously described65. Brieﬂy, imaging was performed on a Nikon TE inverted
microscope using a 100 × , 1.49 NA TIRF objective lens (Nikon UK Ltd.).
Excitation at 640 nm (Toptica Photonic AG, Graefelﬁng, Germany) was used for
Alexa Fluor®647 and 561 nm (Oxxius SLIM-561) for Alexa Fluor®568. Laser beams
were collimated and combined by dichroic mirrors and expanded to illuminate the
sample for wideﬁeld ﬂuorescence microscopy. A 405 nm (120 mW) (Mitsubishi
Electronics Corp., Tokyo, Japan) laser was used as reactivation source. The
ﬂuorescence light in the detection path was separated from the illumination light
by a dichroic ﬁlter cube (Semrock multi-edge dichroic Di01-R405/488/561/635-
25×36 followed by a FF01-446/523/600/677-25 ﬁlter, Semrock, Rochester NY,
USA) and was subsequently ﬁltered further using additional bandpass ﬁlters
(Semrock BP-607/35-25 or BP-642/35-25 for Alexa Fluor®647 and Alexa
Fluor®568 respectively). An electron-multiplying charge-coupled device (EM-
CCD) camera (Andor iXon DV887 ECS-BV, Andor, Belfast, Northern Ireland) was
used for detection. The excitation intensity was 2 kW/cm2 for the 640 nm laser and
5 kW/cm2 for the 561 nm laser. Single-molecule photoswitching of the Alexa
Fluor® 647 and Alexa Fluor® 568 were performed in thiol-containing switching
buffer66 using 100 mM mercaptoethylamine (MEA) in PBS, adjusted to pH 10
using 1M KOH. Imaging was performed in highly inclined (HiLo) illumination
mode67. Overall, 16,000 image frames with exposure times between 7.18 and 20 ms
were recorded and subsequently reconstructed using either rapidSTORM 3.368 or
the open-source rainSTORM software developed in-house69 written in MATLAB
(The MathWork Inc., Natick, USA). Image overlays were assembled in FIJI70,
experiments described were repeated at least three times and all images were
processed as described in the following section.
Image analysis. Western blots were analyzed in FIJI70. For the analysis of
synaptosomal alpha-synuclein and VAMP2 distribution, individual synaptosomes
and their associated ﬂuorophore localizations as found by rapidSTORM were
segmented from the aligned overlay-images using a custom-written Matlab script.
From the data ﬁles, the size for alpha-synuclein distribution and VAMP2 dis-
tribution per synaptosomes were measured using a cluster analysis algorithm with
Ripley’s K function as cluster size metric71. In short, the algorithm measures the
Euclidian distances between each localization with every other one. A histogram of
the distances is then generated and normalized by a histogram as expected from
randomly placed localizations at the same mean density. The maximum distance
value of the normalized histogram then yields a measure for the radius of the
localization clusters. For image analysis of synaptic vesicles, the spot detector
plugin of the image analysis software ICY was used to identify vesicles72,73, fol-
lowed by analysis using an in-house MATLAB script to calculate the number of
vesicles within a 250 nm radius (see code for image analysis of synaptic vesicle
STED images in Supplementary Methods). Analysis of alpha-synuclein and
synaptotagmin-1 in ventral midbrain neurons was performed using the particle
analysis plugin of the image analysis software FIJI70. For co-localization analysis,
the Coloc 2 plugin was used74, based on Pearson’s correlation analysis.
ThT assay and SEC-HPLC quantiﬁcation of alpha-synuclein monomer. The
aggregation of alpha-synuclein was measured by Thioﬂavin T (ThT) assay. Brieﬂy,
10 µM ThT was incubated with 100 µL of 100 µM alpha-synuclein with 2.5 mM
CaCl2 or 1 mM EGTA with and without 1 µL 3.3 mg/mL SV. Assays were per-
formed in non-binding, clear bottom, black 96-well plates (PN 655906 Greiner Bio-
One GmbH, Essen, Germany) which were sealed with an Ampliseal transparent
microplate sealer (Greiner Bio-One GmbH). Plates were incubated with orbital
shaking at 300 rpm at 37 °C and the readings of ThT ﬂuorescence intensity at 486
nm were collected every 16 min for 300 cycles in the top excitation/emission mode
at a focal height of 5.5 mm. Excitation was set at 440 nm with two ﬂashes using
10% of the excitation light (Envision 2104 Multilabel Reader, PerkinElmer, Turku,
Finland). Experiments were repeated three times with six replicates for each
condition. The lag time was calculated by extension of a linear ﬁt to the elongation
phase, passing through the baseline using the equation: y= a+ b * x. k1 (nucleation
rate constant) and k2 (growth rate constant) were calculated from the
Finke–Watzky two-step model ﬁtted to sigmoidal curves of ThT ﬂuorescence25,75
using the equation below:
½Bt ¼ ½A0 
k1
k2
þ ½A0
1þ k1k2 ½A0 expðk1 þ k2 A½ 0tÞ
;
where [B]t is the concentration of product, [A]0 is the concentration of reactant at
time 0 h, k1 is the nucleation rate constant and k2 the elongation rate constant.
10 µL samples of alpha-synuclein ﬁbrils were taken from each condition of the
ThT assay and imaged by TEM as described above. Then, samples were removed
from the wells and centrifuged at 21,100×g for 1 h at RT to pellet ﬁbrils and
oligomers. The supernatant was removed for quantitative analysis by size exclusion
chromatography (SEC). SEC analysis was performed on Agilent 1260 Inﬁnity
HPLC system (Agilent Technologies LDA UK Limited, Stockport, UK) equipped
with an autosampler and a diode-array detector using BioSep-SEC-2000s column
(Phenomenex, Macclesﬁeld, UK) in phosphate-buffered saline (Gibco® PBS,
Thermo Fischer Scientiﬁc) at 1 mL/min ﬂow rate. The elution proﬁle was
monitored by UV absorption at 220 and 280 nm. Remaining monomer
concentration of alpha-synuclein was calculated from a calibration curve.
Remaining monomer concentration for samples with SVs could not be calculated
due to the presence of contaminating SV proteins obscuring the monomeric alpha-
synuclein chromatographic proﬁle.
Statistics. Statistical analysis was performed using GraphPad Prism 6.07
(GraphPad Software, Inc., La Jolla, CA, USA). Values are given as mean ± s.e.m.
unless otherwise stated. Either two-tailed t-test or one-way ANOVA with
Tukey’s post-hoc correction were used as indicated. Signiﬁcance was considered at
p < 0.05.
Data availability. All relevant data are available from the authors.
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